Danaher Co. (NYSE:DHR) Position Increased by Stokes Family Office LLC

Stokes Family Office LLC increased its position in shares of Danaher Co. (NYSE:DHR) by 8.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,225 shares of the conglomerate’s stock after acquiring an additional 165 shares during the period. Stokes Family Office LLC’s holdings in Danaher were worth $515,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. BKM Wealth Management LLC purchased a new stake in shares of Danaher during the fourth quarter worth $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher during the fourth quarter worth $29,000. OFI Invest Asset Management acquired a new position in Danaher during the third quarter worth $30,000. Rakuten Securities Inc. acquired a new position in Danaher during the fourth quarter worth $36,000. Finally, BluePath Capital Management LLC acquired a new position in Danaher during the third quarter worth $44,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of Danaher stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the completion of the transaction, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Teri List sold 3,289 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now directly owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 107,273 shares of company stock worth $26,813,819. Company insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on DHR. Robert W. Baird raised their price target on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday, April 24th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. KeyCorp lifted their target price on Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Raymond James raised their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Finally, Royal Bank of Canada raised their price target on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Price Performance

NYSE:DHR traded up $1.54 during mid-day trading on Friday, reaching $248.38. The stock had a trading volume of 1,787,817 shares, compared to its average volume of 2,914,990. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. The stock has a market capitalization of $183.97 billion, a PE ratio of 42.10, a P/E/G ratio of 3.80 and a beta of 0.83. The stock has a 50-day simple moving average of $248.59 and a two-hundred day simple moving average of $232.00.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter last year, the business posted $2.36 earnings per share. On average, equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date was Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.